13651-07-5

Basic information

• Product Name: Ethanone, 2,2-dibromo-1-(3-nitrophenyl)-
• CAS NO: 13651-07-5
• Molecular Formula: C8H5Br2NO3
• Molecular Weight: 322.941
• Mol File: 13651-07-5.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Ethanone, 2,2-dibromo-1-(3-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2,2-dibromo-1-(3-nitrophenyl)-(13651-07-5)
• EPA Substance Registry System: Ethanone, 2,2-dibromo-1-(3-nitrophenyl)-(13651-07-5)

Safety Data

• Hazardous Substances Data: 13651-07-5(Hazardous Substances Data)

Upstream product

• 586-39-0 1-nitro-3-vinyl-benzene 
• 121-89-1 3-Nitroacetophenone 
• 7471-32-1 m-nitroacetophenone oxime 
• 2227-64-7 3'-nitro-2-bromoacetophenone 
• 13665-04-8 2,2-dibromoacetophenone 

Downstream Products

• 42164-79-4 3-nitromandelic acid 
• 3532-31-8 3-nitrobenzoyl azide 
• 27993-92-6 3-(3-nitrophenyl)quinoxalin-2(1H)-one 

Relevant articles and documents

Preparation method of alpha, alpha-dibromoketone

The invention belongs to the field of preparation of fine chemical products and synthesis of pharmaceutical intermediates and relates to a preparation method of novel alpha, alpha-dibromoketone, in particular to a method for converting olefin into alpha, alpha-dibromoketone by use of dibromohydantoin or N-bromosuccinimide. Compared with the reported methods, the method has the advantages that rawmaterials are easy to obtain and low in cost, used reagents have smaller toxicity, and the method has greater cost and environmental protection advantages and wide application prospects.

High-Potency Phenylquinoxalinone Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators

We previously identified phenylquinoxalinone CFTRact-J027 (4) as a cystic fibrosis transmembrane conductance regulator (CFTR) activator with an EC50 of ～200 nM and demonstrated its therapeutic efficacy in mouse models of constipation. Here, structure-activity studies were done on 36 synthesized phenylquinoxalinone analogs to identify compounds with improved potency and altered metabolic stability. Synthesis of the phenylquinoxalinone core was generally accomplished by condensation of 1,2-phenylenediamines with substituted phenyloxoacetates. Structure-activity studies established, among other features, the privileged nature of a properly positioned nitro moiety on the 3-aryl group. Synthesized analogs showed improved CFTR activation potency compared to 4 with EC50 down to 21 nM and with greater metabolic stability. CFTR activators have potential therapeutic indications in constipation, dry eye, cholestatic liver diseases, and inflammatory lung disorders.

Directing group assisted copper-mediated aroylation of phenols using 2-bromoacetophenones

A new directing group assisted method for the synthesis of aryl esters is described. In this Cu(ii)-mediated reaction, 2-formylphenols and 2-acetylphenols are easily converted into aryl esters via treatment with a new aroylating agent 2-bromoacetophenone.